VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, previously vice president of research and development, will lead advancement of the company’s proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period.
Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the company’s oncology pipeline and advance BiTAC(R) candidates toward clinical development. The appointment comes as VERAXA seeks to transition from a discovery-stage company to a clinical-stage biotech, leveraging its BiTAC platform which combines bispecific T cell engager and ADC technologies.
"We are thrilled to welcome Christoph to the executive team," said the company in a statement. "His deep expertise in antibody engineering and immuno-oncology will be instrumental as we advance our BiTAC candidates toward the clinic." Erkel's background includes successful management of complex research programs, which VERAXA believes will accelerate the development of next-generation therapeutics for solid tumors.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company's pipeline includes bispecific T cell engagers, bispecific ADCs, and other innovative formats, all guided by quality-by-design principles. The BiTAC(R) platform is a registered trademark of VERAXA Biotech GmbH.
For more information, visit the full press release at https://nnw.fm/cR1RS. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties, and actual results may differ materially. See the company's SEC filings for risk factors.
